Violette Shelia M. 4

What Happened
Shelia M. Violette, Chief Scientific Officer of Q32 Bio, was awarded 37,500 restricted stock units (RSUs) on February 24, 2026. The RSUs were granted at $0.00 per unit (total reported value $0) and represent a contingent right to receive one share of common stock per RSU upon vesting. This was an equity compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-24; Filing date (Form 4): 2026-03-20 (appears to be filed late relative to the transaction date).
• Grant size and price: 37,500 RSUs granted at $0.00 (no cash paid).
• Vesting (Footnote F1): RSUs vest in four equal installments — 25% at 6 months from the Feb 24, 2026 grant date, 25% at 12 months, 25% at 24 months, and 25% at 36 months. Each RSU converts to one share upon vesting.
• Ownership note (Footnote F2): Some shares are held by Violette Holdings LLC. The reporting person is a manager of that LLC and disclaims beneficial ownership except to the extent of any pecuniary interest.
• Shares owned after transaction: not specified in the provided filing.

Context
RSU grants are standard employee compensation and do not represent an immediate cash purchase or sale; value is realized only as RSUs vest (and, if converted, when shares are sold). Because this is a grant (code A), it is informational about compensation but does not by itself signal buying or selling intent. The late filing may affect timeliness transparency for investors.